Evaluating the Impact of Non-COPD Medications on COPD Management
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 09/2024
End Date: Ongoing
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
Collaboration: Brigham and Women's Hospital
Activity Type: Research
Activity Description
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the US, yet therapeutic options are limited. The advent of electronic health data has brought an unprecedented opportunity to accelerate drug discovery and identify new therapeutic options for COPD among existing drugs (drug repurposing). Building on state-of-the-art methods for causal inference and existing claims data sources, supplemented with EHR data and deeply phenotyped data from COPDGene, we will develop, test, and implement an analytics and data infrastructure to efficiently evaluate non-COPD medications for COPD.Audience
General Audience: Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
It was funded through the National Heart, Lung and Blood Institute and funds to be allotted to grantees.Impact Analysis
Results of their programs are in progress.Advice or Lessons Learned
In process.Contact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland